Belite Bio received a bullish initiation from Canaccord Genuity with a 'Buy' rating and a $303 price target, significantly above its current trading price. This positive analyst coverage is driven by the potential launch of its lead eye-disease drug, tinlarebant, for Stargardt disease type 1 (STGD1), which has received Priority Review from the FDA.
Belite Bio (BLTE) experienced a significant surge in its stock price following a bullish initiation from Canaccord Genuity. Analyst Whitney Ijem assigned a 'Buy' rating and a $303 price target, citing the strong potential of tinlarebant for Stargardt disease type 1 (STGD1). The FDA's acceptance of the marketing application with Priority Review and a PDUFA date of February 12, 2027, provides a clear near-term catalyst. This news is highly impactful for BLTE as it validates the drug's potential and provides a strong financial outlook, with projected U.S. sales of $6 billion by 2033. The long-term opportunity is further bolstered by potential launches in Japan and other markets, and the geographic atrophy (GA) indication as a future catalyst, though competition in GA is higher. Traders see a clear opportunity in the short term due to the analyst upgrade and the upcoming PDUFA date, while long-term investors are eyeing the substantial revenue projections and pipeline expansion.